An orally bioavailable inhibitor of PARP1 and PARP2
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

ABT-888 (hydrochloride)

Item No. 11505

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-[(2R)-2-methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide, dihydrochloride
CAS Number
912445-05-7
Synonyms
  • Veliparib
Molecular Formula
C13H16N4O • 2HCl
Formula Weight
317.2
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 0.25 mg/mlDMSO: 15 mg/mlEthanol: 0.1 mg/mlPBS (pH 7.2): 10 mg/ml
λmax
269, 292 nm
SMILES
NC(C1=CC=CC2=C1N=C([C@@]3(NCCC3)C)N2)=O.Cl.Cl
InChi Code
InChI=1S/C13H16N4O.2ClH/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12;;/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17);2*1H/t13-;;/m1../s1
InChi Key
DSBSVDCHFMEYBX-FFXKMJQXSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $49

    Add

    5 mg

    $120

    Add

    10 mg

    $157

    Add

    25 mg

    $294

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Poly(ADP-ribose) polymerases (PARPs) have diverse roles in cellular processes, including DNA repair and apoptosis.1,2 ABT-888 is an orally bioavailable inhibitor of PARP1 and PARP2 (Kis = 5.2 and 2.9 nM, respectively).3 It enhances apoptosis and autophagy in response to treatments that cause DNA breaks, including radiation and DNA alkylation.4,5 ABT-888 also acts synergistically with chemotherapies to increase the lethal effects of radiation in cancer cells.6,7

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Davar, D., Beumer, J.H., Hamieh, L., et al. Role of PARP inhibitors in cancer biology and therapy. Curr. Med. Chem. 19(23), 3907-3921 (2012).

    2. Javle, M., and Curtin, N.J. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther. Adv. Med. Oncol. 3(6), 257-267 (2011).

    3. Donawho, C.K., Luo, Y., Penning, T.D., et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13(9), 2728-2737 (2007).

    4. Albert, J.M., Cao, C., Kim, K.W., et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 13(10), 3033-3042 (2007).

    5. Liu, X., Luo, X., Shi, Y., et al. Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. Cancer Biol. Ther. 7(6), 934-941 (2008).

    6. Shelton, J.W., Waxweiler, T.V., Landry, J., et al. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 86(3), 469-476 (2013).

    7. Shunkwiler, L., Ferris, G., and Kunos, C. Inhibition of poly(ADP-ribose) polymerase enhances radiochemosensitivity in cancers proficient in DNA double-strand break repair. Int. J. Mol. Sci. 14(2), 3773-3785 (2013).

    Product Citations

    Kremer, D.M., Nelson, B.S., Lin, L., et al. GOT1 inhibition primes pancreatic cancer for ferroptosis through the autophagic release of labile iron. bioRxiv (2020).